HoxA5 Inhibitors
The chemical class HoxA5 Inhibitors refers to compounds that can indirectly inhibit the Homeobox protein Hox-A5 by influencing cellular processes or pathways that HoxA5 is involved in. HoxA5 is involved in the BMP, RA, and Notch signaling pathways. Therefore, chemicals that can inhibit these pathways can be considered indirect inhibitors of HoxA5. Noggin, LDN-193189, and DMH1 are inhibitors of the BMP signaling pathway, potentially leading to the inhibition of HoxA5. Noggin is an antagonist of BMPs, while LDN-193189 and DMH1 are small molecule inhibitors of BMP type I receptors ALK2 and ALK3, respectively.
Citral, BMS-493, AGN 193109, and Palovarotene can inhibit the RA signaling pathway, potentially leading to the inhibition of HoxA5. Citral is an antagonist of Retinoic acid, while BMS-493 and AGN 193109 are pan-retinoic acid receptor antagonists. Palovarotene is a selective RARγ agonist, which can inhibit the RA signaling pathway. DAPT, RO4929097, LY411575, L685,458, and Compound E are gamma-secretase inhibitors that can inhibit the Notch signaling pathway, thereby potentially leading to the inhibition of HoxA5. These inhibitors prevent the cleavage of Notch, leading to the inhibition of the Notch signaling pathway
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Citral | 5392-40-5 | sc-252620 | 1 kg | $212.00 | ||
Citral is an antagonist of Retinoic acid and can inhibit the RA signaling pathway, which can lead to the inhibition of HoxA5. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor, which can inhibit the Notch signaling pathway, leading to the inhibition of HoxA5. | ||||||
BMS 493 | 215030-90-3 | sc-361124 sc-361124A | 10 mg 50 mg | $459.00 $1428.00 | 7 | |
BMS-493 is a pan-retinoic acid receptor antagonist that can inhibit the RA signaling pathway, potentially leading to the inhibition of HoxA5. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
RO4929097 is a gamma-secretase inhibitor that can inhibit the Notch signaling pathway, potentially leading to the inhibition of HoxA5. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $198.00 $473.00 | 6 | |
LY411575 is a potent gamma-secretase inhibitor, which can inhibit the Notch signaling pathway, potentially leading to the inhibition of HoxA5. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP receptor inhibitor, which can inhibit the BMP signaling pathway and potentially lead to the inhibition of HoxA5. | ||||||
L-685,458 | 292632-98-5 | sc-204042 sc-204042A | 1 mg 5 mg | $337.00 $1000.00 | 4 | |
L685,458 is a potent gamma-secretase inhibitor that can inhibit the Notch signaling pathway, potentially leading to the inhibition of HoxA5. | ||||||
Compound E | 209986-17-4 | sc-221433 sc-221433A sc-221433B | 250 µg 1 mg 5 mg | $124.00 $342.00 $967.00 | 12 | |
Compound E is another potent gamma-secretase inhibitor, which can inhibit the Notch signaling pathway, potentially leading to the inhibition of HoxA5. | ||||||